Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totaling 11,793 shares, a decrease of 97.2% from the April 30th total of 423,802 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 637,751 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

CHGCY has been the topic of several analyst reports. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Up 3.0%

OTCMKTS CHGCY traded up $0.71 on Wednesday, reaching $24.63. 131,973 shares of the stock were exchanged, compared to its average volume of 231,129. Chugai Pharmaceutical has a one year low of $19.50 and a one year high of $34.84. The firm has a market capitalization of $81.07 billion, a PE ratio of 27.37 and a beta of 0.63. The company’s 50-day simple moving average is $26.51 and its two-hundred day simple moving average is $27.36.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.